替尔泊肽治疗的2型糖尿病患者糖尿病视网膜病变早期恶化:一项真实世界队列研究
这项回顾性真实世界队列研究将3435例接受替尔泊肽治疗≥180天的2型糖尿病患者与3434例未暴露者按1:1匹配。调整既定危险因素后,替尔泊肽与新发增殖性糖尿病视网膜病变(PDR)风险升高相关(OR 2.15,95%CI 1.24–3.74,p<0.01),但在基线无视网膜病变者中新发视网膜病变风险降低(OR 0.73,95%CI 0.62–0.86,p<0.001),与轻度非增殖性病变进展无显著关联。
要点
- 替尔泊肽暴露者新发PDR发生率为1.1%(n=33),未暴露者为0.5%(n=17)。
- 调整后替尔泊肽与新发PDR风险升高相关(OR 2.15,95%CI 1.24–3.74,p<0.01)。
- 基线无视网膜病变者中,替尔泊肽与新发视网膜病变风险降低相关(OR 0.73,95%CI 0.62–0.86,p<0.001)。
核心结论
- 替尔泊肽治疗与新发PDR风险升高相关,尤其在轻度非增殖性糖尿病视网膜病变伴黄斑病变(R1M1)或中度至重度非增殖性病变伴或不伴黄斑病变(R2M0、R2M1)者中。
- 进展风险升高支持按早期糖尿病视网膜病变治疗研究(ETDRS)标准转诊眼科专科医生。
研究设计与样本
- 回顾性队列研究,使用真实世界临床数据,将3435例接受替尔泊肽治疗≥180天的2型糖尿病患者与3434例未暴露者按性别、糖尿病病程、视网膜病变状态、HbA1c、视网膜筛查次数和降糖药物使用进行1:1匹配。
- 采用条件logistic回归分析新发糖尿病视网膜病变和视网膜病变进展。
主要发现
- 研究人群基线血糖控制良好(平均HbA1c 56.1±15.8 mmol/mol [7.28±1.43%])。
- 新发增殖性糖尿病视网膜病变(PDR,分级R3M0、R3M1)在替尔泊肽暴露者中发生率为1.1%(n=33),未暴露者为0.5%(n=17)。
- 多因素分析调整既定危险因素后,替尔泊肽与新发PDR显著相关(OR 2.15 [95%CI 1.24, 3.74],p<0.01)。
- 在起始治疗时无糖尿病视网膜病变(R0M0)者中,多因素分析显示替尔泊肽与新发视网膜病变风险降低相关(OR 0.73 [95%CI 0.62, 0.86],p<0.001)。
- 在轻度非增殖性糖尿病视网膜病变(NPDR,分级R1M0或R1M1)者中,替尔泊肽与视网膜病变进展无显著关联。
关键数值与推荐
- 新发PDR定义为分级R3M0、R3M1。
- 无糖尿病视网膜病变定义为R0M0。
- 轻度NPDR定义为R1M0或R1M1。
- 中度至重度NPDR定义为R2M0、R2M1。
临床怎么用
- 作者结论指出,替尔泊肽治疗导致新发PDR风险显著增加,尤其在轻度NPDR伴黄斑病变(R1M1)或中度至重度NPDR伴或不伴黄斑病变(R2M0、R2M1)者中。
- 作者指出进展风险升高支持按ETDRS标准转诊眼科专科医生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Early worsening of diabetic retinopathy (EWDR) has been described during treatment with glucagon-like peptide-1 receptor agonists including subcutaneous semaglutide. Whether EWDR occurs after initiating treatment with the potent glucagon-like peptide 1 / gastric inhibitory polypeptide receptor agonist tirzepatide is unknown. METHODS: In this retrospective cohort study using real-world clinical data, we matched 3435 tirzepatide-exposed (≥180 days treatment) individuals with type 2 diabetes 1:1 with 3434 tirzepatide-unexposed individuals for sex, diabetes duration, retinopathy status, HbA1c, number of retinal screening episodes and use of glucose-lowering medications. New-onset diabetic retinopathy and retinopathy progression were explored using conditional logistic regression. RESULTS: Individuals included in the study had tight baseline glycaemic control (mean HbA1c 56.1 ± 15.8 mmol/mol [7.28 ± 1.43%]). New-onset proliferative diabetic retinopathy (PDR) (grade R3M0, R3M1) occurred in 1.1% of tirzepatide-exposed (n=33) and 0.5% of tirzepatide-unexposed (n=17) individuals. Tirzepatide was significantly associated with new-onset PDR in multivariate analysis after adjustment for established risk factors (OR 2.15 [95% CI 1.24, 3.74], p<0.01). However, tirzepatide was also associated with reduced odds of new onset of retinopathy (OR 0.73 [95% CI 0.62, 0.86], p<0.001) in individuals without diabetic retinopathy (R0M0) at initiation in multivariate analysis, and was not significantly associated with retinopathy progression in individuals with mild non-proliferative diabetic retinopathy (NPDR, grade R1M0 or R1M1). CONCLUSIONS/INTERPRETATION: Tirzepatide therapy resulted in significantly increased odds of incident PDR, particularly in individuals with mild NPDR with maculopathy (grade R1M1), or moderate-to-severe NPDR with or without maculopathy (grade R2M0, R2M1). The increase in odds of progression would justify specialist ophthalmologist referral by Early Treatment Diabetic Retinopathy Study (ETDRS) criteria.
引用
- Buckley AJ, Tan GD, Gruszka-Goh M, et al. Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study. Diabetologia. 2025. PMID: 40637847. doi:10.1007/s00125-025-06466-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。